Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03142165 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants
A Phase 1 study of Fibrosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03142165: Completed Phase 1 study of Fibrosis, sponsored by Bristol-Myers Squibb.
NCT03142165 is a Phase 1 study of Fibrosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants, below the 218-participant average among 10 other Fibrosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03142165, a Phase 1 study of Fibrosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.
Primary Outcome
measured by incidences
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Diphenhydramine
- DRUG Famotidine
- DRUG BMS-986263
Study Locations (1)
California
- Wcct Global, Llc - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2017-11-29 |
| Phase | Phase 1 |
What the finished NCT03142165 record still lists
NCT03142165 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 218-participant average among 10 other Fibrosis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Fibrosis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03142165 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03142165 about?
NCT03142165 is a clinical study titled "A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants". The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.
What is the current status of trial NCT03142165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-05-11. Estimated completion is 2017-11-29.
What conditions does trial NCT03142165 study?
This clinical trial studies the following conditions: Fibrosis.
What interventions are being tested in trial NCT03142165?
The interventions under investigation include: Placebo (OTHER), Diphenhydramine (DRUG), Famotidine (DRUG), BMS-986263 (DRUG).
Who is sponsoring clinical trial NCT03142165?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03142165 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03142165's enrollment target sits among peer trials
33 8th of 10 higher than 3 of 10 other Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
RECRUITING · Phase 2
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
-
A Study of Mosliciguat in PH-ILD
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI